ShockWave Medical (SWAV) Stock Declined in Q4 Amid Extraordinary Revenue Growth - InvestingChannel

ShockWave Medical (SWAV) Stock Declined in Q4 Amid Extraordinary Revenue Growth

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. Small-cap stocks posted solid returns in the fourth quarter for the first time in 2022. The Russell 2000 Growth Index was up 4.11% trailing the Russell 2000 Value Index, which returned 8.39% in the quarter. For the year 2022, small-cap stocks posted disappointing results. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.

Carillon Eagle Small Cap Growth Fund highlighted stocks like ShockWave Medical, Inc. (NASDAQ:SWAV) in the Q4 2022 investor letter. Headquartered in Santa Clara, California, ShockWave Medical, Inc. (NASDAQ:SWAV) is a medical device company. On February 1, 2023, ShockWave Medical, Inc. (NASDAQ:SWAV) stock closed at $191.36 per share. One-month return of ShockWave Medical, Inc. (NASDAQ:SWAV) was -6.60%, and its shares gained 32.94% of their value over the last 52 weeks. ShockWave Medical, Inc. (NASDAQ:SWAV) has a market capitalization of $6.916 billion.

Carillon Eagle Small Cap Growth Fund made the following comment about ShockWave Medical, Inc. (NASDAQ:SWAV) in its Q4 2022 investor letter:

ShockWave Medical, Inc. (NASDAQ:SWAV) develops products to treat calcified cardiovascular disease. Despite reporting extraordinary revenue growth in the quarter, the magnitude of the increase and the forward guidance given were not enough for elevated expectations, and investors who had made money in the stock through early November decided to take some profits.”

VILevi/Shutterstock.com

ShockWave Medical, Inc. (NASDAQ:SWAV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 34 hedge fund portfolios held ShockWave Medical, Inc. (NASDAQ:SWAV) at the end of the third quarter, which was 27 in the previous quarter.

We discussed ShockWave Medical, Inc. (NASDAQ:SWAV) in another article and shared Baron Funds’ views on the company. In addition, please check out our hedge fund investor letters Q4 2022 page for more investor letters from hedge funds and other leading investors.

 

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire